Responses
Abstracts Accepted for Publication
SLE, Sjögren's and APS - treatment
AB0423 Nobility, A Phase 2 Trial To Assess The Safety and Efficacy of Obinutuzumab, A Novel Type 2 Anti-CD20 Monoclonal Antibody (MAB), in Patients (PTS) with ISN/RPS Class III or IV Lupus Nephritis (LN)
Compose a Response to This Article
Other responses
No responses have been published for this article.